GlassScriptPhysician profile
Jack R Gould
NPI 1235241258
$4,100.81
in general payments reported to CMS, 2019-2025
33 companies · $447 in 2025
The $447 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $315 · 2021: $733 · 2022: $777 · 2023: $563 · 2024: $331 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,340.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,085.65 | 2019-2025 | |
| Exeltis, USA INC. | $333.04 | 2019-2025 | Slynd |
| Celularity INC. | $312.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $257.25 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $243.70 | 2021-2025 | |
| Astellas Pharma US INC | $178.51 | 2019-2025 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $175.27 | 2021-2024 | Injectafer |
| Therapeuticsmd, INC. | $139.99 | 2019-2022 | |
| Evofem Biosciences, INC. | $128.44 | 2021-2025 | Phexxi, Solosec, Phexx |
| Sumitomo Pharma America, INC. | $120.20 | 2023-2025 | Myfembree |
| Amgen INC. | $104.35 | 2019-2025 | Evenity |
| Organon LLC | $97.36 | 2022-2025 | Nexplanon, Nuvaring |
| Coopersurgical, INC. | $93.89 | 2019-2023 | Paragard T 380a |
| Vertical Pharmaceuticals, LLC | $86.94 | 2019 | |
| Myovant Sciences INC. | $78.09 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $76.67 | 2022-2023 | |
| Allergan, INC. | $75.17 | 2019-2020 | |
| Scynexis, INC. | $69.02 | 2022 | |
| Hologic Sales and Service, LLC | $64.94 | 2019-2021 | |
| Lupin INC. | $44.31 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $44.20 | 2019-2020 | |
| Avion Pharmaceuticals | $41.67 | 2019-2022 | |
| Coloplast Corp | $36.34 | 2021 | |
| Sage Therapeutics, LLC | $34.35 | 2024 | |
| Exact Sciences Corporation | $34.06 | 2025 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $27.67 | 2021 | |
| Baudax Bio INC. | $24.99 | 2022 | |
| Dilon Technologies, INC. | $22.70 | 2025 | Hemoblast Bellows |
| Roche Diagnostics Corporation | $17.20 | 2021 | |
| Channel Medsystems, INC. | $16.29 | 2024 | |
| Millicent US INC | $13.04 | 2019 | |
| Medicem INC. | $12.39 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Gould listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.